SEC Company Response from Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425) (MIRM) — Jan 6, 2020
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Date: Jan. 6, 2020 · CIK: 0001759425 · Accession: 0001193125-20-002347
AI Filing Summary & Sentiment
File numbers found in text: 333-235825
Letter
VIA EDGAR Division of Corporation Finance Mary Beth Breslin Re: Mirum Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-235825) Request for Acceleration of Effective Date
Dear Ms. Yale and Ms. Breslin:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mirum Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern time, on January 8, 2020, or as soon thereafter as possible, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Jason Kent and Kristin VanderPas of Cooley LLP to make such a request on its behalf. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request.
Once the Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP at (858) 550-6044, or in his absence, Kristin VanderPas of Cooley LLP at (415) 693-2097.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
[Signature page follows]
Very truly yours,
Mirum Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
MIRUM PHARMACEUTICALS, INC.
950 Tower Lane, Suite 1050
Foster
City, California 94404
January 6, 2020
VIA
EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Dorrie Yale
Mary Beth Breslin
Re:
Mirum Pharmaceuticals, Inc.
Registration Statement on Form S-1 (File
No. 333-235825)
Request for Acceleration of Effective Date
Dear Ms. Yale and Ms. Breslin:
Pursuant to
Rule 461 under the Securities Act of 1933, as amended, Mirum Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the
above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern time, on January 8,
2020, or as soon thereafter as possible, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Jason Kent and Kristin VanderPas of
Cooley LLP to make such a request on its behalf. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request.
Once the Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP at (858) 550-6044, or in his absence, Kristin VanderPas of Cooley LLP at (415) 693-2097.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s
request for acceleration of the effectiveness of the Registration Statement.
[Signature page follows]
Very truly yours,
Mirum Pharmaceuticals, Inc.
/s/ Christopher Peetz
By:
Christopher Peetz
Title:
President and Chief Executive Officer
[Signature Page to Acceleration Request]